timothy sykes logo
Strata Skin Sciences: Why A Sudden Move? Thumbnail
G Google News

Strata Skin Sciences: Why A Sudden Move?

BRYCE TUOHEY•UPDATED SEP. 2, 2025, 9:18 AM ET
Reviewed by Tim Sykesand Fact-checked by Matt Monaco

Strata Skin Sciences Inc.’s stocks have been trading up by 54.62 percent as investors gain confidence from promising market developments.

Highlights of Recent Developments

  • The drive to secure temporary codes for its XTRAC excimer laser expands Strata Skin Sciences’ reach, enhancing access and usage.

  • Market expansion is on the cards as Strata seeks broader Medicare and private payer acceptance for XTRAC, potentially affecting over 30 million individuals.

  • Amidst the growth strategies, Strata navigates through a legal battle concerning alleged false advertising with competitor LaserOptek.

Candlestick Chart

Live Update At 09:18:18 EST: On Tuesday, September 02, 2025 Strata Skin Sciences Inc. stock [NASDAQ: SSKN] is trending up by 54.62%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Earnings Report: A Brief Look

As millionaire penny stock trader and teacher Tim Sykes, says, “Be patient, don’t force trades, and let the perfect setups come to you.” Trading successfully often requires discipline and a strategic approach. It’s crucial for traders to avoid impulsive decisions and to wait for the right opportunities to present themselves. Taking time to analyze and understand market trends can lead to more informed trading decisions and ultimately yield better results. The quote emphasizes the importance of waiting for the perfect setups, a key principle in achieving success in trading.

Strata Skin Sciences’ recent financial performance indicates a company in transition, trying to manage its finances amid ambitious strategies. Total revenue clocked in at approximately $33.56 million, where the cost of revenue made up a significant portion. Gross profit was still robust at around $4.3 million while operating expenses soared to nearly $6.53 million, reflecting Strata’s investment in growth.

Unsurprisingly, the net income stood at a negative value, hinting at heavy reinvestment and strategic expenditures as the company battles for market share. This expense-driven approach impacted earnings per share, notedly in the negative, but it’s not unusual amidst game-changing strategic plays.

More Breaking News

Financial strength, though slightly strained, remains manageable. With a total debt-to-equity ratio standing at a noteworthy 53.09%, the company appears to ensure it has a solid foothold to leverage its assets wisely. Strata’s quick ratio of 0.7 exhibits a slight concern; however, the overarching narrative focuses on durable growth despite immediate frictional features.

Market Drivers: A Delicate Dance

Strata’s seek for Medicare expansion and the drive to tackle potential 30M patients could be a big turnaround. By attempting to diversify engagement potential, Strata is setting its sensors to catch a fair share of the dermatological advancements windfall. However, the cost that comes with such expansions is evident.

The data indicates a high burst of activity, with stock values rising quickly over the days. For instance, close prices increased from $1.65 to $2.38 within a week, painting a picture of the market’s responsive enthusiasm toward Strata’s recent endeavors.

However, significant risks remain. Notably, a cumbersome litigation exercise with LaserOptek harbors potential financial drains which could affect short-term liquidity. Navigating these risks requires finesse but could hold substantial underlying reward if litigation outcomes favor Strata.

Legal Battles: The Competitor Gauntlet

Amid remarkable market moves, Strata pivots with a lawsuit alleging competitor misinformation tactics. Such legal endeavors ensure fair market play, but they also come loaded with uncertainties and potential distractions. The impact on share price remains a mixed bag, primarily contingent upon litigation proceedings and resolutions.

Notwithstanding, strategic operations focusing on securing pivotal Medicare codes can buffer reputational challenges, placing Strata at potential leverage against competitors and market impressions.

Conclusion: Straining Forward

In wrapping, Strata’s embarked on a transformative trajectory reflecting their intent to broaden horizons via tactical Medicare expansions while contending with competitor waters. The financial metrics capture intricate phases which, with strategic DMARDs, position Strata for growing relevance and possibly lucrative monetization. As millionaire penny stock trader and teacher Tim Sykes, says, “It’s not about how much money you make; it’s about how much money you keep.”

This once again highlights the intertwined nature of strategic expansion and short-term financial juggle-struggle. Those contemplating Strata’s evolution must navigate the propitious outcomes with an awareness of potential volatilities—a growth story in its infant burst of life. Traders looking to understand Strata’s trajectory should heed this advice, ensuring that while revenue may be on their minds, the critical aspect of retaining earnings isn’t overlooked.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”